Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 24 von 31

Details

Autor(en) / Beteiligte
Titel
Major thrombocytopenia after balloon-expandable transcatheter aortic valve replacement: Prognostic implications and comparison to surgical aortic valve replacement
Ist Teil von
  • Catheterization and cardiovascular interventions, 2015-01, Vol.85 (1), p.130-137
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2015
Quelle
MEDLINE
Beschreibungen/Notizen
  • Objectives We sought to investigate the magnitude and clinical importance of thrombocytopenia post transcatheter aortic valve replacement (TAVR). Background Thrombocytopenia has been observed after TAVR but has not been well studied. Methods Major thrombocytopenia (platelet count <100 × 109/L) was studied following aortic valve interventions in a single center. Changes in platelets were compared in 246 patients undergoing balloon‐expandable TAVR and a similar population of 57 cases undergoing surgical aortic valve replacement (SAVR in the US PARTNER IA trial). Results An early drop in platelets was seen on the day of intervention. The drop day 1 post procedure was similar but slightly greater with SAVR vs. TAVR. In both platelet counts continued to drop, reaching a nadir of approximately 50–60% of the baseline platelet count at day 2–3, starting to recover after day 5. Early major thrombocytopenia occurred post TAVR in 37% of patients but was not significantly related to major bleeding (OR 0.89, 95% CI 0.51–1.60, P = 0.69) or risk of stroke (HR 0.61, 95% CI 0.16–2.20, P = 0.45); there was a trend to greater acute kidney injury (OR 1.76, 95% CI 0.95–3.26, P = 0.073) and mortality (HR 1.47, 95% CI 0.98–2.22, P = 0.065). Major thrombocytopenia was persistent in 7.7% of patients and this was independently associated with mortality (HR 3.65, 95% CI 1.63–8.16, P = 0.002). Conclusions Post‐TAVR thrombocytopenia is a common phenomenon and its magnitude appears similar to that seen after SAVR. It is most often transient, not associated with adverse sequelae and, unless persistent, should be managed in an expectant fashion. © 2014 Wiley Periodicals, Inc.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX